Christopher K Lippincott1, Melissa B Miller2, Elena B Popowitch3, Colleen F Hanrahan4, Annelies Van Rie4. 1. Institute for Global Health and Infectious Diseases. 2. Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill. 3. Clinical Microbiology/Immunology Laboratories, University of North Carolina Health Care, Chapel Hill. 4. Department of Epidemiology, University of North Carolina at Chapel Hill.
Abstract
BACKGROUND: In the United States, individuals with presumptive pulmonary tuberculosis are placed in airborne infection isolation (AII) and assessed by smear microscopy on 3 respiratory specimens collected 8-24 hours apart. Xpert MTB/RIF assay (Xpert) on 1, 2, or 3 specimens may be more efficient for determining AII discontinuation. METHODS: This single-center, observational cohort study of inpatients with presumptive pulmonary tuberculosis enrolled adults with 1 or more sputum specimens submitted for smear microscopy. Smear microscopy and Xpert were performed on each sputum specimen. Clinicians were blinded to Xpert results. The primary endpoint was AII duration. Secondary endpoints were laboratory processing time, strategy-based tuberculosis detection, and sensitivity and specificity. RESULTS: Among 207 subjects, the median AII duration was 68.0 hours (interquartile range [IQR], 47.1-97.5) for smear microscopy compared with 20.8 hours (IQR, 16.8-32.0) for the 1-specimen Xpert, 41.2 hours (IQR, 26.6-54.8) for the 2-specimen Xpert, and 54.0 hours (IQR, 43.3-80.0) for the 3-specimen Xpert strategies (P ≤ .004). Median laboratory processing time for smear microscopy was 2.5 times as long as Xpert (P < .001). The 2- and 3-specimen Xpert and smear microscopy strategies captured all 6 tuberculosis cases. The 1-specimen Xpert strategy missed 1 case. No difference was observed between smear microscopy and Xpert in sensitivity or specificity for detection of Mycobacterium tuberculosis. CONCLUSIONS: Xpert-based strategies significantly reduced AII duration compared with the smear-based strategy. The 2-specimen Xpert strategy was most efficient in minimizing AII time while identifying all tuberculosis cases among individuals with presumptive tuberculosis in this low-burden setting.
BACKGROUND: In the United States, individuals with presumptive pulmonary tuberculosis are placed in airborne infection isolation (AII) and assessed by smear microscopy on 3 respiratory specimens collected 8-24 hours apart. Xpert MTB/RIF assay (Xpert) on 1, 2, or 3 specimens may be more efficient for determining AII discontinuation. METHODS: This single-center, observational cohort study of inpatients with presumptive pulmonary tuberculosis enrolled adults with 1 or more sputum specimens submitted for smear microscopy. Smear microscopy and Xpert were performed on each sputum specimen. Clinicians were blinded to Xpert results. The primary endpoint was AII duration. Secondary endpoints were laboratory processing time, strategy-based tuberculosis detection, and sensitivity and specificity. RESULTS: Among 207 subjects, the median AII duration was 68.0 hours (interquartile range [IQR], 47.1-97.5) for smear microscopy compared with 20.8 hours (IQR, 16.8-32.0) for the 1-specimen Xpert, 41.2 hours (IQR, 26.6-54.8) for the 2-specimen Xpert, and 54.0 hours (IQR, 43.3-80.0) for the 3-specimen Xpert strategies (P ≤ .004). Median laboratory processing time for smear microscopy was 2.5 times as long as Xpert (P < .001). The 2- and 3-specimen Xpert and smear microscopy strategies captured all 6 tuberculosis cases. The 1-specimen Xpert strategy missed 1 case. No difference was observed between smear microscopy and Xpert in sensitivity or specificity for detection of Mycobacterium tuberculosis. CONCLUSIONS: Xpert-based strategies significantly reduced AII duration compared with the smear-based strategy. The 2-specimen Xpert strategy was most efficient in minimizing AII time while identifying all tuberculosis cases among individuals with presumptive tuberculosis in this low-burden setting.
Authors: Karen R Steingart; Megan Henry; Vivienne Ng; Philip C Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark Perkins; Mohamed Abdel Aziz; Madhukar Pai Journal: Lancet Infect Dis Date: 2006-09 Impact factor: 25.071
Authors: S R Mase; A Ramsay; V Ng; M Henry; P C Hopewell; J Cunningham; R Urbanczik; M D Perkins; M A Aziz; M Pai Journal: Int J Tuberc Lung Dis Date: 2007-05 Impact factor: 2.373
Authors: Michael K Leonard; Kathleen B Egan; Ekaterina Kourbatova; Nancy White; Patricia Parrott; Carlos Del Rio; Henry M Blumberg Journal: Am J Infect Control Date: 2006-03 Impact factor: 2.918
Authors: J Daniel Kelly; Shou-Yean Grace Lin; Pennan M Barry; Chris Keh; Julie Higashi; John Z Metcalfe Journal: Am J Respir Crit Care Med Date: 2014-12-01 Impact factor: 21.405
Authors: Lelia H Chaisson; David Duong; Adithya Cattamanchi; Marguerite Roemer; Margaret A Handley; Dean Schillinger; Matthew Sur; Phong Pham; Mary Ann Lin; L Elizabeth Goldman; Judy Quan; Saida Perez; Michael Healy; Julie Higashi; Lisa Winston; Barbara Haller; Anne F Luetkemeyer; J Lucian Davis Journal: JAMA Intern Med Date: 2018-10-01 Impact factor: 21.873
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Varsha Kumar; Tracy L Dalton; Lori R Armstrong; Amy Whitesell; Rongxia Li; Angela M Starks Journal: Open Forum Infect Dis Date: 2021-10-20 Impact factor: 4.423
Authors: Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson Journal: Clin Microbiol Rev Date: 2018-01-31 Impact factor: 26.132
Authors: Yingda L Xie; Wendy A Cronin; Michael Proschan; Richard Oatis; Silvia Cohn; Scott R Curry; Jonathan E Golub; Clifton E Barry; Susan E Dorman Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 20.999